Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03378739 · ClinicalTrials.gov registry record
Inova Cardiogenic Shock Registry (INOVA SHOCK)
A clinical trial of Cardiogenic Shock, sponsored by Inova Health Care Services.
- Recruiting
- Registry status
- 3,000
- Enrollment target
- 1
- Study location
NCT03378739: Recruiting study of Cardiogenic Shock, sponsored by Inova Health Care Services.
NCT03378739 is a study of Cardiogenic Shock that is actively recruiting participants, run by Inova Health Care Services. The registered enrollment target is 3,000 participants, above the 447-participant average among 16 other Cardiogenic Shock trials with a reported enrollment target (571% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03378739, a study of Cardiogenic Shock, is actively recruiting participants, sponsored by Inova Health Care Services.
- RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 1
- Study location
Study Summary
To collect retrospective clinical outcomes related to acute decompensated heart failure cardiogenic shock, acute myocardial infarction cardiogenic shock and compare current versus historical survival rates. To collect Inova Heart and Vascular Institute (IHVI) site specific outcomes before and after initiation of the Cardiogenic Shock team on January 1, 2017. To collect outcomes related to implementation of mechanical circulatory support versus no circulatory intervention and type of intervention (extracorporeal membrane oxygenation (ECMO) versus intracorporeal axial-flow (Impella). • Assess survival at three time points.
Primary Outcome
To create an archive of retrospective clinical outcomes (acute decompensated heart failure cardiogenic shock, or acute myocardial infarction cardiogenic shock) and compare current versus historical survival rates.
Conditions Studied
Interventions
- PROCEDURE Cardiogenic Shock team activation
Study Locations (1)
Virginia
- Inova Fairfax Hospital - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2099-12-31 |
What NCT03378739 shows while recruiting
NCT03378739 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 447-participant average among 16 other Cardiogenic Shock trials with a reported enrollment target (571% higher).
The record links to 1 condition, with Cardiogenic Shock appearing as the primary indexed condition, and to 1 intervention - of which Cardiogenic Shock team activation is the first listed.
NCT03378739 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT03378739 about?
NCT03378739 is a clinical study titled "Inova Cardiogenic Shock Registry (INOVA SHOCK)". To collect retrospective clinical outcomes related to acute decompensated heart failure cardiogenic shock, acute myocardial infarction cardiogenic shock and compare current versus historical survival rates. To collect Inova Heart and Vascular Institute (IHVI) site specific outcomes before and after...
What is the current status of trial NCT03378739?
This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2018-01-01. Estimated completion is 2099-12-31.
What conditions does trial NCT03378739 study?
This clinical trial studies the following conditions: Cardiogenic Shock.
What interventions are being tested in trial NCT03378739?
The interventions under investigation include: Cardiogenic Shock team activation (PROCEDURE).
Who is sponsoring clinical trial NCT03378739?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03378739 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiogenic Shock
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03378739's enrollment target sits among peer trials
3,000 2nd of 16 the highest of 16 other Cardiogenic Shock trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiogenic Shock trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Cardiac Power Output in Cardiogenic Shock Patients
RECRUITING · Early Phase 1
-
Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure
RECRUITING
-
Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR
RECRUITING
-
Left Ventricular Physiological Effects of Veno-Arterial Extracorporeal Membrane Oxygenation Support During Cardiogenic Shock
RECRUITING
-
Physiology of Unloading VA ECMO Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI